New Alzheimer’s Treatments Are Driving a Shift in Earlier Detection and Clinician Education Engagement
June 25, 2025 |
June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.
Authors: Katie Lucero, Chief Impact Officer, Medscape; Jonathan Chee, Principal Account Manager; Anna Druet, Senior Science Writer; Briana Kelly, Senior Healthcare Consultant; Alicia Sloughfy, Senior Healthcare Consultant; Evan Woodward, MD, Senior Clinical Product Manager
Part one of a two-part series. Up next: a whitepaper delving into disparities in treatment and screening.
For years, efforts to screen for Alzheimer’s disease have lagged behind clinical need. Though over 6.9 million Americans age 65 and older are living with Alzheimer’s, the disease often goes undiagnosed. Historically, a lack of treatment options have led to limited screening by providers, even though early diagnosis can offer substantial value for many patients. In 2017, the CDC reported that only 47% of primary care physicians included cognitive assessment as part of their standard protocol for adults age 65 and older. For many families, a diagnosis still tends to come late in the disease progression. Yet early detection can provide access to support services, time to plan, and more informed care decisions.
This analysis marks the first part of a two-part series; a white paper delving into disparities in treatment and screening will be published in early fall.
New Therapies, New Incentives to Screen
The inertia may be shifting with the introduction of new treatment options. The 2023 FDA approval of lecanemab (Leqembi) — an anti-amyloid therapy (AAT) and the first approved treatment shown to reduce the rate of disease progression for early Alzheimer’s — marked a turning point. This was followed by Donanemab (Kisunla), which received FDA Breakthrough Therapy designation in 2024. Together, these therapies represent a new clinical pathway for slowing disease progression.
To understand how care is evolving in response to these approvals, we analyzed national screening trends surrounding the 2023 launch of lecanemabi. Using our MapLab® platform and our Healthcare Map® which tracks the journeys of more than 330 million U.S. patients, we assessed screening rates in the 18 months before and after July 2023. Additionally, we leveraged Medscape Education’s proprietary platform, PULSE — which reaches 95% of validated NPIs — to examine provider engagement between January 2022 and July 2024.
Among patients age 65 and older in the 18 months before and after the second DMT approval:
- Cognitive screening rose by 10%. These structured assessments support early diagnosis and help distinguish Alzheimer’s from other causes of cognitive decline
- Gene and protein biomarker testing increased by 23%. In the same cohort and timeline, more individual patients received tests like APOE genotype and plasma p-tau. While not required for treatment eligibility, these tests help clinicians assess risk and monitor disease progression, reflecting a broader move toward precision medicine
- Amyloid beta pathology testing surged more than 13-fold. In the same cohort and timeline, a far greater number of patients underwent confirmatory testing via PET imaging or cerebrospinal fluid analysis — now a prerequisite for accessing new therapies — signaling a rising demand for DMT
Impact of Clinician Education on Screening
To evaluate how new treatment approvals influence clinician knowledge and education-seeking behavior, we matched 80% of Medscape-registered clinicians who screen, diagnose, and treat Alzheimer’s with Komodo’s Healthcare Map®. These clinicians were responsible for the care of 91% of patients in the Komodo cohort.
We examined clinician content consumption, knowledge scores, and confidence ratings in the 18 months before and after the second DMT approval. Among the nearly 800,000 healthcare professionals identified as involved in the Alzheimer’s patient journey:
- Consumption of Alzheimer’s-specific independent medical education (IME) increased by 18% among clinicians involved in the Alzheimer’s journey post-approval. In contrast, those not involved in Alzheimer’s care showed a 6% increase
- Screening knowledge showed a 92% relative improvement post-approval. Clinicians scored 26% on screening-related questions pre-approval, which rose to 50% in the 18 months post-approval. Following participation in IME, knowledge scores improved by an additional 26% relative to the post-approval baseline (from 50% to 63%). Knowledge scores reflect the percentage of correct responses on three multiple-choice questions about the topic of education
- Clinician confidence in screening rose from 2.58 to 3.07 (on a five-point scale) after IME participation in the 18 months post-approval — a 19% increase. Confidence was self-rated on a scale from 1 (not at all confident) to 5 (very confident) in screening for cognitive impairment
Turning Insights Into Action
Brain and Alzheimer’s Awareness Month highlights the urgent need for improved care, and real-world evidence will play a central role in tracking how new therapies reshape clinical practice. Komodo’s tools allow stakeholders to measure the real-time impact of drug launches, surface care gaps, and drive earlier intervention across all patient populations.
Ongoing clinician education will play a critical role as the standard of care continues to evolve. Recent research has found that independent learning platforms like Medscape Education, which offers timely updates on emerging therapies and changing diagnostic protocols, help providers stay current in a fast-moving landscape. Access to accurate, up-to-date information remains essential for informed decision-making in clinical practice, especially when it comes to recognizing, screening for, and treating early signs of Alzheimer’s disease.
To explore more on screening through the lens of real-world evidence, see how disparities in diagnostic testing affect outcomes across diseases in our analysis of genetic testing gaps in ovarian cancer.
To see more articles like this, follow Komodo Health on X, LinkedIn, or YouTube, and visit Perspectives on their website.
About Medscape Education
Medscape Education is the leading online platform for continuing medical education (CME) and continuing education (CE), trusted by millions of healthcare professionals worldwide. With more than 30 speciality-specific learning destinations, it offers thousands of free, accredited courses for physicians, nurses, pharmacists, and other healthcare professionals. Medscape Education delivers high-impact, evidence-based education designed to support clinical decision-making, improve patient outcomes, and keep healthcare professionals current in a rapidly evolving medical landscape.
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
30 Years of Innovation in Education at HLTH Europe
The Medscape Education Global team will be travelling to Amsterdam for the HLTH Europe 2025 conference to showcase the power and value of CME. As pioneers in clinician education for...
Medscape Online Continuing Medical Education Led to New Diagnoses in Alzheimer’s Disease
Medscape Education has recently published a study looking at the real-world impact of online continuing medical education on Alzheimer's disease diagnosis. Read the full article here. The study, published in...
Medscape Oncology at ASCO 2025: Driving Innovation, Education & Better Patient Outcomes
Medscape Oncology is making a powerful impact at ASCO 2025, bringing seven high-impact symposia, new research insights, and the return of the Medscape Fellows Program—all aimed at educating the next...
Medscape Celebrates Eight Groundbreaking Publications at ATS 2025 International Conference
Medscape Education is proud to announce the presentation of eight innovative educational research publications at the American Thoracic Society (ATS) 2025 International Conference, held May 16–21 in San Francisco, CA....
The Future of CME in the Virtual World
The future of CME is here—and it’s personal, powerful, and primed for impact. In an era where clinician time is stretched thin, AI and digital innovation are transforming continuing medical...
Stronger Together: Medscape Education Celebrates Accomplishments in Rare Disease and Anticipates the World Health Assembly Adoption of the Resolution on Rare Diseases
Medscape Education is proud to be showcasing the power of working together in rare disease education and advocacy by co-hosting a side event at the 78th World Health Assembly in...
Intersection of Leadership and Advocacy: Driving Change Together for Women
We can’t talk about challenges to women’s reproductive health without acknowledging that we’re living in unprecedented times, say two mission-driven women’s healthcare leaders. Stephanie Sober, MD, MSHP, Global Director, Medical...
Shaping the Future of Hematology and Women’s Health
Changes in the healthcare world are likely to limit opportunities for young researchers, especially women.Three leaders in hematology — Belinda Avalos, Sarah O’Brien, and Marty Liggett — share the initiatives...
Are Clinicians Still Feeling the Burn? A Look at HCP Mental Health and Well-Being
One of the most critical topics to address in health care today is the mental health and well-being of physicians and other healthcare professionals. The 2020 COVID-19 pandemic shined a...
Medscape Women’s Health Joins Supporters in Sponsorship of SWHR’s 2025 Gala
Medscape Women’s Health is proud to announce its sponsorship of the Society for Women's Health Research (SWHR) 2025 Gala, which took place on Wednesday, April 30, 2025, celebrating 35 Years...